From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Inspiritol is an experimental drug that aims to treat post-viral illness and respiratory distress.[1][2] Inspiritol is both the name of the company company the drug and the name of the drug. Inspiritol has been reported to have been used experimentally on a small number of ME/CFS patients, long COVID patients, and people with flu, COPD or asthma.[1]

Theory[edit | edit source]

Inspiritol aims to alter the oral microbiome to reduce levels of bacteria that have previously been linked to inflammation. In a recent small study whole genome sequencing was used to sample the oral microbiome of patients who tested positive for COVID-19 at an emergency room, fourteen of the patients later developed long COVID. The study's long COVID patients were found to have changes 19 species of bacteria in their oral microbiome that were not found in patients without long COVID.[3][4]

Inspiritol consists of a number of different substances, some of which are believed to have anti-inflammatory, antiviral, or antibacterial effects.[1]

Evidence[edit | edit source]

No clinical trials or case studies of Inspiritol have been published yet.

Clinicians[edit | edit source]

Inspiritol has been used in clinical trials by the following ME/CFS researchers:

Risks and safety[edit | edit source]

Inspiritol remains in clinical trials so the side effects and risks are largely unknown, and it has not yet been given FDA approval.

Costs and availability[edit | edit source]

Inspiritol is an inhaled drug which is highly restricted due to not yet being FDA-approved.[2]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 1.2 1.3 "New inhaled drug created to treat Respiratory distress & post viral illness". Inspiritol®. Retrieved October 30, 2021.
  2. 2.0 2.1 2.2 "Inspiritol Effective In COVID-19, Long-COVID And ME/CFS Patients". News4. Retrieved October 30, 2021.
  3. Haran, John P.; Bradley, Evan; Zeamer, Abigail L.; Cincotta, Lindsey; Salive, Marie-Claire; Dutta, Protiva; Mutaawe, Shafik; Anya, Otuwe; Meza-Segura, Mario (October 22, 2021). "Inflammation-type dysbiosis of the oral microbiome associates with the duration of COVID-19 symptoms and long COVID". JCI Insight. 6 (20). doi:10.1172/jci.insight.152346. ISSN 0021-9738.
  4. Fessendener, Jim (October 22, 2021). "UMass Chan study finds association between long-COVID symptoms and altered oral microbiome". UMass Chan Medical School. Retrieved October 30, 2021.